September 27, 2016 12:27 PM ET

Life Sciences Tools and Services

Company Overview of Crown Bioscience, Inc.

Company Overview

Crown Bioscience, Inc., a preclinical CRO, provides drug discovery and development services to biotech and pharmaceutical partners focusing on oncology and metabolic disease therapeutic areas. The company’s proprietary HuPrime, HuKemia, HuBase, HuMark, HuTrial, and HuSignature platforms enable lead optimization and translational strategies to deliver clinical candidates. It offers oncology services, such as oncology databases, Ex vivo services, human surrogate trials, in vitro and in vivo services, preclinical formulations, translational research, and drug discovery services; and metabolic disease services, including in vivo and in vitro services, cardiovascular and metabolic disease (CVMD) ...

3375 Scott Boulevard

Suite 108

Santa Clara, CA 95054

United States

Founded in 2006

Phone:

855-827-6968

Fax:

888-882-4881

Key Executives for Crown Bioscience, Inc.

Chief Executive Officer
Co-Founder, President and Chief Strategy Officer
Age: 52
Chief Financial Officer
Age: 58
Chief Operating Officer
Age: 51
President of International Institute of Biomedical Research (IIBR) and Senior Vice President of Cardiovascular & Metabolic Diseases (CVMD) Research
Compensation as of Fiscal Year 2016.

Crown Bioscience, Inc. Key Developments

Crown Bioscience Launches New Interactive Feature for XenoBase in Vitro Models

Crown Bioscience has published a further enriched version of its XenoBase, the online database collating cell line and cell line derived xenograft model data. The newly added module complements the existing database's powerful search options of publicly profiled data (gene expression, copy number and mutation) as well as proprietary histopathology, in vivo pharmacology, tumor growth and molecular pathology data for over 200 validated cell line derived xenograft models and for more than 1,000 tumor cell lines. With the new XenoBase feature, users will now be able to directly search and interact with dose response curves and IC50 data for over 290 cell lines, providing the ability to rapidly review and select the most appropriate model for their in vitro studies. Registered XenoBase users can already take advantage of the new feature, while new clients can simply send a request to register to start using the service from the company website.

Crown Bioscience Announces Executive Changes

Crown Bioscience announced that President, Dr. Jean Pierre Wery, has now moved into the role of Chief Executive Officer. In addition to Dr. Wery's recent nomination as CEO, Dr. Alex Wu, co-founder of CrownBio takes the role of President and Chief Strategy Officer, while Ms. Eva Ho has been appointed Chief Financial Officer. Ho brings years of experience in financial planning and analysis, having led the financial operations of well renowned global companies. Ho will take on Mr. Bing Zhu's previous role, who has now been appointed Chief Operating Officer.

Crown Bioscience Inc. Announces Board Appointments

Crown Bioscience Inc. has announced the appointment of Amar Thyagarajan, Ph.D., and Sandeep Sinha, Ph.D., to its team. Thyagarajan joins CrownBio as the associate director of product marketing and strategy. With extensive experience in bringing new products to market, he is responsible for the strategic and scientific marketing of CrownBio's cardiovascular and metabolic disease (CVMD) portfolio. Thyagarajan brings extensive scientific and senior product management experience with genetically engineered models used in neuroscience and CVMD drug discovery and safety and toxicology studies. Sinha is joining the team as scientific director and is responsible for providing direction to CrownBio's technical teams to build better partnerships with clients to execute successful CVMD programs. Prior to joining CrownBio, Sinha worked at Eli Lilly as a medical science liaison for diabetes and cardiovascular disease.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
February 26, 2016
PreClinOmics, Inc.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Crown Bioscience, Inc., please visit www.crownbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.